BSGM - BioSig Technologies Inc. Announces New Appointments to its Now Fully Constituted Board of Directors which is Comprised of 5 Board Members 3 Independent | Benzinga
Westport, CT, May 03, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "the Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced new appointments to its now fully constituted board of directors (the "Board"), which is comprised of a total of five (5) directors, three (3) of whom are classified as independent directors. The final compositions of the committees to the Board will be determined in the very near term.
Commenting on the newly assembled Board, BioSig's CEO, Mr. Anthony Amato stated, "The Company is proud to introduce its new members on our Board, which includes talented individuals with years of experience across a broad array of industries and professions. The Board is now compliant with the rules and regulations that govern the standards acceptable to major U.S. Exchanges, including three (3) highly qualified independent directors, and I am confident that our directors will uphold their strategic, financial, and managerial responsibilities to the Company. BioSig continues to realize important and meaningful progress and is working with great urgency to create lasting shareholder value."
Board Member #1, Anthony Amato
Mr. Anthony Amato is a business leader and entrepreneurial thinker with an intuitive ability to rapidly assess challenges and identify growth opportunities. He quickly sees organizational vision and understands goals, taking appropriate ownership and action required to guide the team, achieving aggressive targets and performance levels. Mr. Amato has hands-on executive skills at engaging and influencing key stakeholders to not only grow business but also to optimize profits.
Mr. Amato founded InQuest Science in March 2017 and then acquired Bridge Associates International Pharmaceutical Consulting in March 2020. He is the former director of Sales for Mesa Labs (MLAB) in Denver CO, a Nasdaq listed corporation that specializes in providing quality control products and services to ensure the safety and efficacy of equipment used in hospitals, pharmaceutical, medical device manufacturers, blood banks, laboratories, pharmacies, and industrial facilities.
In July of 1999, Mr. Amato founded Amega Scientific Corporation. He grew the company from a startup operation to a worldwide industry leader.Mr. Amato developed and managed a staff with multiple North American offices, establishing R&D, production, logistics, administration, and sales. Clients included pharmaceutical, biotech, hospitals, government facilities, and research universities. Amega Scientific was a leading innovator for the environmental monitoring system industry. Amega Scientific was an ISO 17025 corporation instituting GXP requirements. Amega Scientific was acquired by Mesa Labs in November 2013.
Mr. Amato graduated from Glassboro State College in New Jersey in 1989, with a dual degree in business management and finance. Mr. Amato's outstanding interpersonal, business development, team building, and management skills make him an asset to the Company's board of directors.
Board Member #2, Chris Baer
Mr. Chris Baer brings more than 25 years of commercial experience in the medical device space across both large publicly held and smaller privately held organizations. He currently serves as the chief commercial officer at CDL Nuclear Technologies. He started in this role in April ...